TrialFrontiers in immunology2023

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.

Yanfei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.